🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2...
Status
Unknown
Location
University of Alabama Birmingham
Start Date
2021-05-07
Trial ID
NCT04835584
This study evaluates either KRT-232 or TL-895 in treatment naïve patients w...
Status
Unknown
Location
Innovative Clinical Research Institute
Start Date
2021-04-13
Trial ID
NCT04878003
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2...
Status
Recruiting
Location
Goshen Center for Cancer Care
Start Date
2021-02-23
Trial ID
NCT04502394
Treatments Being Tested
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2...
Status
Active Not Recruiting
Location
The Kirklin Clinic of UAB Hospital
Start Date
2019-01-15
Trial ID
NCT03669965
Treatments Being Tested
This study evaluates navtemadlin as maintenance treatment for patients with...
Status
Recruiting
Location
Kaiser Permanente Center
Start Date
2023-07-17
Trial ID
NCT05797831
Treatments Being Tested
This study evaluates Navtemadlin (KRT-232) in combination with Pembrolizuma...
Status
Withdrawn
Location
Multiple Locations
Start Date
2023-06
Trial ID
NCT05705466
Treatments Being Tested
This phase Ib trial studies the side effects and best dose of navtemadlin w...
Status
Active Not Recruiting
Location
City of Hope Comprehensive Cancer Center
Start Date
2018-02-08
Trial ID
NCT03041688
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2...
Status
Unknown
Location
The Kirklin Clinic of UAB Hospital
Start Date
2019-01-15
Trial ID
NCT03662126
Treatments Being Tested
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2...
Status
Unknown
Location
University of Colorado Anschutz Medical Campus
Start Date
2019-03-19
Trial ID
NCT03787602
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2...
Status
Terminated
Location
Florida Cancer Specialists - 3840 Broadway
Start Date
2021-12-06
Trial ID
NCT05027867
Treatments Being Tested